Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, the Company is party to a Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Purchase Agreement”), by and among the Company, Ascent Partners Fund LLC, a Delaware limited lia
How this was made
The 30-second read
Why it matters
The tighter conversion terms reduce potential dilution, which may be viewed positively by shareholders, though the modest financing size limits market impact.
Market read
A niche financing amendment with limited price impact, primarily relevant to PFSA shareholders and noteholders.
What to watch
The amendment does not affect other outstanding notes, and the overall financing size remains modest, limiting broader impact.
Background
Profusa disclosed amendments to its convertible promissory notes, a routine financing update for a micro‑cap biotech.
Ticker impact
Profusa filed an 8‑K reporting amendments to its April 2 and April 20 senior secured convertible notes, raising the floor price to $0.338 and setting a minimum conversion price of $1.20.
likely modest upside as the higher floor reduces dilution risk
The new floor price and minimum conversion price are materially higher than prior terms, which should be viewed favorably by equity investors.
Market effects
May influence other micro‑cap biotech financing structures as investors watch note amendment trends.
Limited to U.S. OTC market where PFSA trades.
Low; the filing is company‑specific with no broader macro implications.
Counterpoint
Higher conversion floor could be seen as a red flag that management anticipates lower share price, potentially pressuring the stock.
Key entities
- companyProfusa, Inc.
Biotech firm issuing the amended convertible notes.
- investorAscent Partners Fund LLC
Counterparty to the note amendments.